

Abteilung "Haematologie u. Onkologie"

Journalbeiträge

1. Bäsecke J, Conradi I, Bramlage CP, Scheel AK, Trümper L (2005) [Polycythemia vera and D-dimer-negative thromboembolism]. *MED KLIN*, 100(10): 672-5.
2. Bäsecke J, Schwieger M, Griesinger F, Schiedlmeier B, Wulf G, Trümper L, Stocking C (2005) AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation. *LEUKEMIA LYMPHOMA*, 46(2): 265-72.
3. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, Stocking C (2005) Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. *BLOOD*, 106(12): 3958-61.
4. Denikus N, Orfaniotou F, Wulf G, Lehmann PF, Monod M, Reichard U (2005) Fungal antigens expressed during invasive aspergillosis. *INFECT IMMUN*, 73(8): 4704-13.
5. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. *BLOOD*, 105(7): 2677-84.
6. Ehrenreich H, Hasselblatt M, Knerlich F, von Ahsen N, Jacob S, Sperling S, Woldt H, Vehmeyer K, Nave KA, Sirén AL (2005) A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain. *P NATL ACAD SCI USA*, 102(3): 862-7.
7. Fischer M, Schwieger M, Horn S, Niebuhr B, Ford A, Roscher S, Bergholz U, Greaves M, Löhler J, Stocking C (2005) Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model. *ONCOGENE*, 24(51): 7579-91.
8. Fröhling S, Schlenk RF, Krauter J, Thiede C, Ehninger G, Haase D, Harder L, Kreitmeier S, Scholl C, Caligiuri MA, Bloomfield CD, Döhner H, Döhner K (2005) Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. *GENE CHROMOSOME CANC*, 42(4): 427-32.
9. Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, Lübbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kündgen A, Mueller T, Haas R, Gattermann N, Aul C (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). *LEUKEMIA*, 19(12): 2223-31.
10. Gregory SA, Trümper L (2005) Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? *ANN ONCOL*, 16(9): 1413-24.
11. Griesinger F, Hennig H, Hillmer F, Podleschny M, Steffens R, Pies A, Wörmann B, Haase D, Bohlander SK (2005) A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. *GENE CHROMOSOME CANC*, 44(3): 329-33.
12. Hagemann T, Balkwill F (2005) MIFed about cancer? *GASTROENTEROLOGY*, 129(5): 1785-7.
13. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ (2005) Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. *DNA CELL BIOL*, 24(11): 766-76.
14. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR (2005) Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. *J IMMUNOL*, 175(2): 1197-205.
15. Henke RT, Maitra A, Paik S, Wellstein A (2005) Gene expression analysis in sections and tissue microarrays of archival tissues by mRNA in situ hybridization. *HISTOL HISTOPATHOL*, 20(1): 225-37.
16. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *BLOOD*, 106(12): 3725-32.
17. Hirschmann-Jax C, Foster AE, Wulf GG, Goodell MA, Brenner MK (2005) A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. *Cell Cycle*, 4(2): 203-5.
18. Holtick U, Vockerodt M, Pinkert D, Schoof N, Stürzenhofecker B, Kussebi N, Lauber K, Wesselborg S, Löffler D, Horn F, Trümper L, Kube D (2005) STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. *LEUKEMIA*, 19(6): 936-44.

Abteilung "Haematologie u. Onkologie"

19. Jung W, Zettl F, Schroers R (2005) [Multiple myeloma -- therapy]. DEUT MED WOCHENSCHR, 130(6): 283-6; quiz 287-90.
20. Krüger WH, Bohlius J, Cornely OA, Einsele H, Hebart H, Massenkeil G, Schüttrumpf S, Silling G, Ullmann AJ, Waldschmidt DT, Wolf HH (2005) Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. ANN ONCOL, 16(8): 1381-90.
21. Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ANN HEMATOL, 84 Suppl 13: 61-6.
22. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL (2005) The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. CANCER RES, 65(22): 10355-62.
23. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhmann U, Reinhardt D (2005) Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. CYTOM PART B-CLIN CY, 63(1): 1-9.
24. Lenk C, Biller-Andorno N, Alt-Epping B, Anders M, Wiesemann C (2005) [Ethics and diagnosis related groups]. DEUT MED WOCHENSCHR, 130(27): 1653-5.
25. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Münz C (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. SCIENCE, 307(5709): 593-6.
26. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stühmer W (2005) Role of voltage-gated potassium channels in cancer. J MEMBRANE BIOL, 205(3): 115-24.
27. Schroers R, Griesinger F, Trümper L, Haase D, Kulle B, Klein-Hitpass L, Sellmann L, Dührsen U, Dürig J (2005) Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. LEUKEMIA, 19(5): 750-8.
28. Schroers R, Hildebrandt Y, Steffens R, Becker S, Ohms G, Bonin F, Haase D, Bertsch HP, Trümper L, Griesinger F (2005) Immunophenotypic and genetic characterization of a CD8 positive mantle cell lymphoma in a patient with concomitant Mycosis fungoides. EUR J HAEMATOL, 75(1): 78-84.
29. Schroers R, Zettl F, Jung W (2005) [Multiple myeloma -- diagnostics]. DEUT MED WOCHENSCHR, 130(6): 278-82; quiz 287-90.
30. Steidl C, Steffens R, Gassmann W, Hildebrandt B, Hilgers R, Germing U, Trümper L, Haase D (2005) Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients. LEUKEMIA RES, 29(9): 987-93.
31. Steidl U, Schroeder T, Steidl C, Kobbe G, Graef T, Bork S, Pechtel S, Kliszewski S, Kuendgen A, Rohr UP, Fenk R, Schroeder M, Haase D, Haas R, Kronenwett R (2005) Distinct gene expression pattern of malignant hematopoietic stem and progenitor cells in polycythemia vera. ANN NY ACAD SCI, 1044: 94-108.
32. Trümper L (2005) [From bench to bedside]. MED KLIN, 100(1): 53.
33. Trümper LH (2005) To irradiate or not to irradiate--that is the question. Nat Clin Pract Oncol, 2(2): 76-7.
34. Vockerodt M, Pinkert D, Smola-Hess S, Michels A, Ransohoff RM, Tesch H, Kube D (2005) The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation. INT J CANCER, 114(4): 598-605.
35. Von Marschall Z, Scholz A, Stacker SA, Achen MG, Jackson DG, Alves F, Schirner M, Haberey M, Thierauch KH, Wiedenmann B, Rosewicz S (2005) Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. INT J ONCOL, 27(3): 669-79.
36. Wieding JU, Matern J, Köstering H, Wermes C, Wenzel E (2005) Retention test Homburg to monitor the adhesive properties of von Willebrand factor after substitution or desmopressin therapy. SEMIN THROMB HEMOST, 31(4): 441-8.
37. Wojnowski L, Kulle B, Schirner M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EK, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmüller J, Hasenfuss G (2005) NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. CIRCULATION, 112(24): 3754-62.
38. Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B (2005) Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. BONE MARROW TRANSPL, 36(3): 271-3.
39. Wulf GG, Sadowski B, von Bonin F, Glass B, Truemper L (2005) Bone marrow side population (SP) cells are donor derived after allogeneic stem cell transplantation in humans. BONE MARROW TRANSPL, 36(2): 179-80.

Abteilung "Haematologie u. Onkologie"

40. Zettl F, Jung W, Schroers R (2005) [Multiple myeloma -- case report]. DEUT MED WOCHENSCHR, 130(6): 277; quiz 287-90.

Habilitationen

1. Schroers R, Identifikation und immunologische Charakterisierung von MHC-Klasse-II-abhängigen T-Helferzellepitopen in tumorassoziierten Antigenen. Habilitation Universität Göttingen 2005.

Medizinische Dissertationen

1. Braulke F, Dr. med., Ergebnisse der paläopathologischen Untersuchungen an den Postcranien der frühneolithischen Erwachsenenskelete aus Wandersleben, Kreis Gotha. Dissertation Universität Göttingen 2005.
2. Kaul S, Dr. med., Inzidenz von MLL-Exon-8-Deletionen bei T-ALL. Dissertation Universität Göttingen 2005.
3. Modlich S, Dr. med., Untersuchung zur Expression des ABC-Transporters ABCA3 in leukämischen Blasten der akuten myeloischen Leukämie. Dissertation Universität Göttingen 2005.
4. von Laffert W, Dr. med., Analyse durchflußzytometrischer Diagnosen der akuten lymphatischen Leukämie. Dissertation Universität Göttingen 2005.
5. Wille T, Dr. med., Das Mainzer Stadienmodell der Schmerzchronifizierung - Untersuchung der Reliabilität mittels einer Itemanalyse. Dissertation Universität Göttingen 2005.

Diplomarbeiten / Masterarbeiten

1. Schoof N, Dipl.-Biol., Analyse der Wirkung des Protein-Tyrosin-Kinase-Inhibitors AG17 in Hodgkin-Lymphomzelllinien. Diplomarbeit Universität Göttingen 2005.
2. Feuerborn A, Dipl.-Biol., Generierung von p21-"knock-down"-Klonen in Hodgkin Lymphom Zelllinien mit Hilfe der siRNA-Technologie und anschließende Analyse. Diplomarbeit Universität Göttingen 2005.